A study of TAK-861 for narcolepsy with cataplexy
Part of Brain & nervous system, Mental health clinical trials.
This trial tests a new medication called TAK-861 for people with narcolepsy type 1 (NT1), which causes sudden muscle weakness (cataplexy) and extreme daytime sleepiness. The study aims to see if TAK-861 can help reduce these symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have narcolepsy with cataplexy (type 1).
- Your body mass index (BMI) is between 18 and 40.
- You have a specific genetic marker (HLA-DQB1*06:02) or low levels of a brain chemical called hypocretin.
- You do not have another medical condition causing sleepiness.
- You do not have serious heart, liver, thyroid, or stomach problems.
- You have not had a seizure, head injury, or certain heart or brain issues.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medication called TAK-360 to help adults with narcolepsy type 1 (a condition that causes extreme daytime sleepiness and sudden muscle weakness called cataplexy) feel more alert during the day. The goal is to see if this treatment is safe and effective for managing narcolepsy symptoms.
This study tests an investigational medication called TAK-360 for people with idiopathic hypersomnia (IH), a sleep disorder that causes excessive daytime sleepiness. The goal is to see if the drug can help reduce sleepiness and improve daily function.
This Phase 2/3 study tests TAK-861 in people with narcolepsy type 1 (NT1) who already completed an earlier TAK-861 trial. The goal is to see if the medicine remains safe and effective for ongoing central (brain-related) sleepiness problems.
This study tests a new medicine called TAK-360 for people with narcolepsy type 2 (narcolepsy without cataplexy). It aims to see if the drug safely reduces daytime sleepiness.
This is a follow-up study for people who already completed a TAK-360 trial for narcolepsy (a sleep disorder causing sudden sleep attacks) or idiopathic hypersomnia (excessive daytime sleepiness). Researchers want to see if continuing TAK-360 remains safe and effective for you.
This study tests a new drug called E2086 to see if it can help reduce daytime sleepiness and sudden muscle weakness in adults with narcolepsy. It involves two groups: people with cataplexy (type 1) and those without (type 2).
Hear when a new Narcolepsy Type 1 (NT1) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.